Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FWY003 dose-ranging study in geographic atrophy secondary to age-related macular degeneration
jRCT2051260096Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in age-related macular degeneration (AMD) comparing FWY003 with Placebo (2 arms). Started Aug 2026; status: recruiting.
02
Drugs
FWY003
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on jRCT2051260096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260096.